SummaryCaffeic acid phenethyl ester (CAPE), an active component in propolis, is known to have anti-tumour, anti-inflammatory and anti-oxidant properties. In this study, the effects of CAPE on the functions of primary human CD4 + T cells were evaluated in vitro. CAPE significantly suppressed interferon (IFN)-g and interleukin (IL)-5 production and proliferation of CD4 + T cells stimulated by soluble anti-CD3 and anti-CD28 monoclonal antibodies in both healthy subjects and asthmatic patients. CAPE inhibited nuclear factor (NF)-kB activation and protein kinase B (Akt) phosphorylation, but not p38 mitogen-activated protein kinase (MAPK) phosphorylation in T cells. CAPE also induced active caspase-3 expression in CD4+ T cells; CCR4 + CD4 + T cells were more sensitive to CAPE induction than CXCR3 + CD4 + T cells. Together, these results indicate that CAPE inhibits cytokine production and proliferation of T cells, which might be related to the NF-kB and Akt signalling pathways, and that CCR4 + CD4 + T cells are more sensitive to CAPE inhibition. This study provides a new insight into the mechanisms of CAPE for immune regulation and a rationale for the use of propolis for the treatment of allergic disorders.
our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.
Anaphylaxis is a systemic allergic reaction that is acute and could be life-threatening. Once diagnosed, avoidance of allergen and carrying an epinephrine auto-injector are recommended. Most anaphylactic reactions are immunoglobulin E (IgE)-mediated and the major triggers include food, medication, insect stings, exercise and vaccines. Here, we present a case of a 38-year-old male, a surgeon, diagnosed as food-related anaphylaxis with a convincing clinical history and the positive serum-specific IgE level to Dermatophagoides pteronyssinus and Dermatophagoides farina allergens. This patient was treated with omalizumab administered subcutaneously. Routine lymphocyte subsets and CD23+ B cells of this patient were evaluated monthly for the consecutive ten months and one year after the last treatment. Our data showed that there was a correlation between the level of CD23+ B cells and the efficacy of omalizumab treatment. The patient had higher percentage of CD23+ B cells and CD23 expression level (86.5 % and MFI 371.9, respectively) during the onset of anaphylaxis. With the omalizumab treatment, both CD23+ B cells and CD23 expression level decreased gradually. The basal levels of CD23+ B cells and CD23 expression dropped to 25.1% and 72.6 MFI, respectively when the patient became recovered one year after the last treatment. Our findings highlight the potential of CD23+ B cells to be the useful parameter to predict the treatment effect of omalizumab in food-related anaphylaxis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.